Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling – Investor’s Business Daily
Investor’s Business Daily |
Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling
Investor’s Business Daily Schwartz noted the stock reaction is likely exacerbated by the resignation of an advisor worried about the therapy. Dr. James Wilson expressed worries over the treatment in January when he resigned from Solid Bio's scientific advisory board. "Solid is … |
